Pregabalin

證據等級: L5

預測適應症: 6 個

Pregabalin: From Neuropathic Pain to Tendinitis

One-Sentence Summary

Pregabalin is a calcium-channel modulator widely used to treat neuropathic pain, epilepsy, and related conditions. The TxGNN model predicts it may be effective for Tendinitis, but currently 0 clinical trials and 6 publications support this specific link, and none of the existing literature directly studies tendinitis as a treatment target.

Quick Overview

Item	Content
Original Indication	Not specified in evidence pack (pregabalin is not currently marketed in this jurisdiction; 0 authorizations on file)
Predicted New Indication	Tendinitis
TxGNN Prediction Score	99.71%
Evidence Level	L4
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Formal mechanism-of-action documentation for pregabalin was not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on the repurposing rationale supplied alongside the prediction, pregabalin binds the α2δ subunit of voltage-dependent calcium channels, reducing release of excitatory neurotransmitters — a mechanism well suited to neuropathic pain and perioperative analgesia.

Tendinitis, however, is primarily a local inflammatory/mechanical injury pain condition rather than a neuropathic pain state, so the mechanistic overlap with pregabalin's calcium-channel action is weak. The supporting literature largely involves pregabalin used for perioperative pain control after orthopedic surgery (e.g., arthroscopic rotator cuff repair) or for unrelated peripheral neuropathies (piriformis syndrome, chemotherapy-induced neuropathy), rather than direct evidence of efficacy against tendinitis pathology itself. This is consistent with the model's own scoring, which places this candidate at evidence level L4 (mechanism/preclinical-level support only) with a "Hold" recommendation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32839073	2021	RCT	J Orthop Sci	Retrospective cohort on pregabalin's analgesic efficacy and opioid-sparing effect after arthroscopic rotator cuff repair — perioperative pain control, not tendinitis treatment per se
34052386	2022	RCT	Arthroscopy	Perioperative oral pregabalin produced pain scores comparable to interscalene brachial plexus block after rotator cuff repair
40818536	2025	Review/Commentary	Arthroscopy	Editorial on piriformis syndrome diagnosis and sciatic neurolysis; tendon involvement discussed but no pregabalin efficacy data
41017607	2025	Case Report	Praxis	Describes fluoroquinolone-associated tendinopathy/disability; pregabalin not directly evaluated
37051935	2023	Case Report	Pain Pract	Posterior femoral cutaneous nerve impingement from running-related tendonitis; nerve pain context, not a tendinitis efficacy study
39703364	2024	Preclinical	Adv Pharmacol Pharm Sci	Plant extract (not pregabalin) attenuates vincristine-induced peripheral neuropathy in rats

Germany Market Information

Pregabalin is currently not marketed in this jurisdiction; no authorization records are available (0 total licenses on file).

Safety Considerations

Please refer to the package insert for safety information. (Note: TFDA label warnings and contraindications for pregabalin are a Blocking-severity data gap, DG001 — this must be resolved before any safety assessment can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic link between pregabalin's calcium-channel modulation and tendinitis (a local inflammatory/mechanical condition) is weak, and no clinical trials or literature directly test pregabalin for tendinitis — existing evidence only covers perioperative pain control or unrelated neuropathies.

To proceed, the following is needed:

TFDA/BfArM label warnings and contraindications (DG001, Blocking)
Formal DrugBank-sourced mechanism-of-action documentation (DG002, High)
A tendinitis-specific preclinical or pilot clinical study to establish direct biological plausibility before any trial design

Additional note: Among the six candidates in this evidence pack, migraine disorder (rank 5, TxGNN score 99.47%) has meaningfully stronger support — an L2 evidence level with multiple pediatric RCTs, a Cochrane systematic review, and preclinical imaging data showing pregabalin inhibits cortical spreading depression (the core pathology of migraine aura). A withdrawn Phase 3 adult trial (NCT00447369) indicates prior development interest but no completed confirmatory data. This candidate may warrant prioritization as a "Research Question" track ahead of tendinitis.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.